"Vindesine"

Treatment of children with refractory/relapse high risk langerhans cell histiocytosis with the combination of cytarabine, vindesine and prednisone. The patients with multisystem and risk organ involvement Langerhans cell histiocytosis (MS-RO + LCH) have poor prognosis. The patients with MS-LCH who failed front-line therapy have a high mortality rate and the standard salvage treatment has not been established. The combination of cytarabine (Ara-c), vincristine (VCR) and prednisone might be effective for refractory/relapse MS-RO + LCH, with low toxicity. We retrospectively analyzed pediatric refractory/relapse MS-RO + LCH patients treated with the low-dose Ara-c (100mg/m/d×5days) or high-dose Ara-c (500mg/m/d×5days) combined with vindesine (VDS) and prednisone in a single center

Phase 2 study of pegylated liposomal doxorubicin plus cyclophosphamide, vincristine/vindesine, and prednisone in newly diagnosed PTCL: 8-year results. Pegylated liposomal doxorubicin (PLD) is a liposome-encapsulated form of doxorubicin with equivalent efficacy and less cardiotoxicity. This phase 2 study evaluated the efficacy and safety of the PLD-containing CHOP regimen in newly diagnosed patients with aggressive peripheral T-cell lymphomas (PTCL). Patients received PLD, cyclophosphamide, vincristine/vindesine, plus prednisone every 3 weeks for up to 6 cycles. The primary endpoint was the objective response rate at the end of treatment (EOT). From September 2015 to January 2017, 40 patients were treated. At the EOT, objective response was achieved by 82.5% of patients, with 62.5% complete

Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma Previously untreated patients with follicular lymphoma are treated with the ZGCVP regimen (zanubrutinib, obinutuzumab, cyclophosphamide, vindesine, prednisolone) for 6 cycles. This is a prospective, single-arm, multi-center, phase II clinical study aiming at evaluating the efficacy and safety of zanubrutinib with GCVP (obinutuzumab, cyclophosphamide, vindesine, prednisolone) in untreated follicular lymphoma (FL). It includes screening (14 days before the first dose), treatment, and follow-up phases. Screening: Recruitment subjects are grade 1-3a, stage III/IV or extensive stage II (unsuitable for radiotherapy) FL patients, with measurable lesions (short axis ≥1.5cm

Preliminary results of G versus GViElC: A phase III trial of gemcitabine associated to vindesine or gemcitabine alone in elderly or poor performance patients with advanced non-small cell lung cancer (NSCLC).

[Clinical Efficacy of Bleomycin, Cyclophosphamide, Vindesine, Ara-C and Dexamethasone for Treatment of Patients with Relapsed Refractory Diffuse Large B Cell Lymphoma]. To investigate the clinical efficacy of bleomycin, cyclophosphamide, vindesine, Ara-C and dexamethasone(BACOD) for treatment of patients with relapsed/refractory diffuse large B cell lymphoma. A total of 56 patients with relapsed efficacy of cyclophosphamide, vindesine and dexamethasone for treatment of patients with relapsed/refractory/diffuse large B cell lymphoma has been confirmed to be satisfactory, suggesting that the continuous venoclysis with BACOD can be apptied to the in clinical treatment.

A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial. Treatment of primary central nervous system lymphoma (PCNSL) in elderly patients remains unsatisfactory. To develop a new high-dose methotrexate (HD-MTX)-based regimen including idarubicin , a phase 1 multicenter dose escalation study was conducted to determine the maximum-tolerated dose (MTD) of idarubicin. Thirty-five immunocompetent patients with PCNSL were enrolled. The median age was 65 years (range, 60-70 years). MTX and vindesine (VDS) were given at the fixed dose of 3 g/m(2) (6-hr intravenous [IV]) and 3 mg/m(2) IV on day 1, respectively. Prednisolone (PRED) was given at the fixed

A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET The experimental drug regimen in this study includes a PD-1 antibody (tislelizumab) single-drug induction treatment period and a PD-1 antibody period (3rd-6th/8th course for PR patients):PD-1 antibody, specification: 100mg/bottle. Usage and dosage: intravenous drip, 100mg each time, QD, d1, d15. AVD regimen Doxorubicin 25mg/m2, d1, d15 intravenous injection Vindesine 3mg/m2, d1, d15 intravenous injection Dacarbazine 0.375mg/m2, d1, d15 intravenous drip In this combined treatment regimen, every 28 days is a treatment cycle, and the PD-1

knowledge. c. According to the G-BA, it cannot be inferred from the available evidence and the written statements of the medical associations that, in accordance with the generally recognized state of medical knowledge, the off-la bel use of rituximab in combination with doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone (R-ACVBP) and of rituximab in combination with cyclophosphamide lymphoma; G-BA: Federal Joint Committee; R-ACVBP: rituximab in combination with doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone; R-CHOEP: rituximab in combination with cyclophosphamide, etoposide, doxorubicin, vincristine and prednisone; R-CHOP: rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone; R-CHP: rituximab in combination with cyclophosphamide

hydrochloride, and prednisolone; COPP=cyclophosphamide, vincristine, procarbazine, and prednisone; COPPEBVCAD-CEC=cyclophosphamide, lomustine, vindesine, melphalan, prednisone, epidoxirubicin, vincristine, procarbazine, vinblastine, and bleomycin; CR=complete response; DFI=disease-free interval; DFS=Disease-free Survival; DSS=Disease-specific Survival; eBEACOPP=escalated-dose BEACOPP; eBEACOPP4+bBEACOPP4= 4

chemotherapy although the effect was more muted at 4%.59 However, the Adjuvant Lung Project Italy (ALPI) study, a RCT conducted in Italy,45 did not demonstrate an OS benefit with adjuvant chemotherapy (HR, 0.96; 95% CI, 0.81 to 1.13; P = .589). This difference may be explained by the toxicity of the chemotherapy regimen used in ALPI (mitomycin, cisplatin, and vindesine) compared with what was used in ANITA (cisplatin and vinorelbine) and IALT (cisplatin doublets with etoposide, vinorelbine, vinblastine, or vindesine). Toxicity (both from the chemotherapy itself and the lack of optimal supportive care medications) likely played an important role in the negative results seen in other earlier trials.58 A MA by the Lung Adjuvant Cisplatin Evaluation (LACE) Collaborative Group, which pooled and analyzed data from

trials examined the interim PET response-adapted strategy in patients with advanced stage Hodgkin lymphoma [33,34]. In the GOELAMS LH 2007 trial, patients with a positive interim FDG PET/CT scan after two cycles of front-line vindesine, doxorubicin, carmustine, etoposide, and 5 methylprednisolone (VABEM) and switched to salvage therapy followed